Mechanistic Insights into a CDK9 Inhibitor Via Orthogonal Proteomics Methods

Area of Science:

• Biochemistry
• Pharmacology
• Chemical Biology

Background:

• Cyclin-dependent kinases (CDKs) are serine/threonine kinases regulated by cyclins.
• CDK9, complexed with cyclins T1, T2, or K, forms P-TEFb, crucial for RNA polymerase II phosphorylation and transcription elongation.
• P-TEFb is a significant therapeutic target due to its role in regulating gene expression.

Purpose of the Study:

• To evaluate the selectivity, target engagement, and downstream effects of a specific CDK9 tool compound.
• To showcase the application of quantitative mass spectrometry in drug discovery for target identification and selectivity profiling.
• To provide guidance on chemical biology and proteomic tools for studying drug lead molecules.

Main Methods:

• Classical affinity purification chemical proteomics
• Kinobeads assay
• Compressed Cellular Thermal Shift Assay (CETSA)-MS
• Limited Proteolysis (LiP)

Main Results:

• Multiple quantitative mass spectrometry approaches were employed.
• The compound demonstrated high affinity and selectivity for the CDK family, particularly CDK9.
• Consistent results across different methods validated CDK9 as the primary target.

Conclusions:

• Proteomic strategies are valuable for drug discovery, enabling target identification and selectivity assessment.
• The studied compound effectively targets CDK9, validating its potential as a therapeutic agent.
• The findings offer insights into CDK biology and the application of advanced proteomic techniques.